Clinical Research Directory

Inclusion Criteria: * Aged 18 to 85 years. * Total PSA (tPSA) level ranging from 3 ng/ml to 20 ng/ml (inclusive). * Underwent prostate MRI at the study institution with complete imaging sequences. * Capable of providing written informed consent. * Patients with PI-RADS 4-5, or PI-RADS 3 combined with PSAD ≥ 0.2 ng/ml², who have undergone prostate biopsy with no diagnosis of clinically significant prostate cancer (csPCa). * Biopsy-naïve patients with PI-RADS 2, or PI-RADS 3 combined with PSAD \< 0.2 ng/ml². Exclusion Criteria: * Pathologically confirmed diagnosis of clinically significant prostate cancer (csPCa). * Contraindications to prostate biopsy or inability to tolerate the procedure. * Current use of 5-alpha reductase inhibitors (5-ARIs). * History of hip replacement, metallic hip arthroplasty, or extensive pelvic orthopedic surgery with metallic hardware, or presence of other implants that would degrade MRI image quality. * Contraindications to bi-parametric MRI (bpMRI) (e.g., severe claustrophobia, cardiac pacemakers).